Model Parameters Estimating on Lyman–Kutcher–Burman Normal Tissue Complication Probability for Xerostomia on Head and Neck Cancer

The purpose of this study is to derive parameters estimating for the Lyman–Kutcher–Burman (LKB) normal tissue complication probability (NTCP) model using analysis of scintigraphy assessments and quality of life (QoL) measurement questionnaires for the parotid gland (xerostomia). In total, 31 patients with head-and-neck (HN) cancer were enrolled. Salivary excretion factor (SEF) and EORTC QLQ-H&N35 questionnaires datasets are used for the NTCP modeling to describe the incidence of grade 4 xerostomia. Assuming that n= 1, NTCP fitted parameters are given as TD50= 43.6 Gy, m= 0.18 in SEF analysis, and as TD50= 44.1 Gy, m= 0.11 in QoL measurements, respectively. SEF and QoL datasets can validate the Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) guidelines well, resulting in NPV-s of 100% for the both datasets and suggests that the QUANTEC 25/20Gy gland-spared guidelines are suitable for clinical used for the HN cohort to effectively avoid xerostomia.

Authors:

• Tsair-Fwu Lee
• Hui-Min Ting
• Pei-Ju Chao
• Jing-Chuan Jiang
• Min-Yuan Chao
• Wen-Cheng Chen
• Long-Chang Chen
• Jia-Ming Wu

Keywords:

• HN
• NTCP
• SEF
• QoL
• QUANTEC

References:

[1] A. Meirovitz, et al., "Grading xerostomia by physicians or by patients
after intensity-modulated radiotherapy of head-and-neck cancer," Int J
Radiat Oncol Biol Phys, vol. 66, pp. 445-453, 2006.
[2] A. Eisbruch, et al., "Xerostomia and its predictors following
parotid-sparing irradiation of head-and-neck cancer," Int J Radiat Oncol
Biol Phys, vol. 50, pp. 695-704, 2001.
[3] A. Niemierko and M. Goitein, "Calculation of normal tissue complication
probability and dose-volume histogram reduction schemes for tissues
with a critical element architecture," Radiother Oncol, vol. 20, pp.
166-176, 1991.
[4] V. Semenenko and X. Li, "Lyman-Kutcher-Burman NTCP model
parameters for radiation pneumonitis and xerostomia based on combined
analysis of published clinical data," Phys Med Biol, vol. 53, p. 737, 2008.
[5] V. Moiseenko, et al., "Treatment planning constraints to avoid xerostomia
in head-and-neck radiotherapy: an independent test of QUANTEC criteria
using a prospectively collected dataset," Int J Radiat Oncol Biol Phys, vol.
82, pp. 1108-1114, 2012.
[6] J. O. Deasy, et al., "Radiotherapy dose-volume effects on salivary gland
function," Int J Radiat Oncol Biol Phys, vol. 76, pp. S58-S63, 2010.
[7] T. F. Lee, et al., "Dual Arc Volumetric-modulated Arc Radiotherapy
(VMAT) of Nasopharyngeal Carcinomas: A Simultaneous Integrated
Boost Treatment Plan Comparison with Intensity-modulated
Radiotherapies and Single Arc VMAT," Clin Oncol, pp. 196-207, 2011.
[8] J. M. Roesink, et al., "Scintigraphic assessment of early and late parotid
gland function after radiotherapy for head-and-neck cancer: a prospective
study of dose-volume response relationships," Int J Radiat Oncol Biol
Phys, vol. 58, pp. 1451-1460, 2004.
[9] K. Bjordal, et al., "Quality of life in head and neck cancer patients:
validation of the European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire-H&N35," J Clin Oncol vol. 17, pp.
1008-1008, 1999.
[10] N. K. Aaronson, et al., "The European Organization for Research and
Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in
international clinical trials in oncology," J Natio Cancer Instit, vol. 85, pp.
365-376, 1993.
[11] F. M. Fang, et al., "Multivariate analysis of quality of life outcome for
nasopharyngeal carcinoma patients after treatment," Radiother Oncol,
vol. 97, pp. 263-269, 2010.
[12] S. W. Leung, et al., "Health-related Quality of life in 640 head and neck
cancer survivors after radiotherapy using EORTC QLQ-C30 and
QLQ-H&N35 questionnaires," BMC cancer, vol. 11, p. 128, 2011.